# Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

> **NCT02249871** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 54 (actual)

## Conditions studied

- Diabetes
- Healthy

## Interventions

- **DRUG:** semaglutide
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT02249871
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-24
- **Primary completion:** 2015-04-01
- **Final completion:** 2015-04-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249871, "Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02249871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*